Data Bytes: Cellectis remains active in allogeneic pipeline for multiple myeloma despite clinical hold

Even with the clinical hold on its Phase I trial of UCARTCS1A, Cellectis remains one of the most active companies developing allogeneic cell therapies for multiple myeloma, with another